New Therapeutic Developments for Relapsed/Refractory Multiple Myeloma

Thank you for your interest in attending the Clinical Care Options’ (CCO) symposium, “New Therapeutic Developments for Relapsed/Refractory Multiple Myeloma,” scheduled in Frankfurt, Germany. Due to the global impact of COVID-19, EHA organizers have decided to host the 25th EHA Congress in a virtual format. 

As such, this live symposium will now be held as 2 virtual live Webinars. The Webinars will still feature the original expert faculty, interactivity, evidence-based content, and panel discussions. When participating in the live Webinars, you will be able to text questions directly to the faculty and the planned agenda allows time for the faculty to discuss and answer submitted questions.

If you’ve previously registered for the live symposium, your registration will be automatically converted to one of the live Webinars. No further action is needed; you will receive an email with a link to join in advance of the Webinar.

We look forward to having you join us for these interactive, live Webinars. In addition, we invite to you visit our Web site to access the many available online hematology and oncology programs and clinical resources.

Thank you,
CCO Member Services

Please note, this internationally-focused program is intended for hematologists, medical oncologists, and other healthcare providers with a primary practice outside of the United States.

Agenda

Faculty

Program Director
Philippe Moreau, MD

Professor of Clinical Hematology
Head,
Hematology Department
University Hospital Hôtel-Dieu
Nantes, France

Faculty
Jesús F. San-Miguel, MD

Director of Clinical and Translational Medicine
Universidad de Navarra
Pamplona, Spain

Faculty
Katja Weisel, MD

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate new and emerging therapies into the treatment of patients with relapsed/refractory multiple myeloma.

Target Audience
This program is intended for global hematologists, medical oncologists, and other healthcare providers who care for patients with MM.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for R/R MM
  • Explain the mechanism of action of newer classes of agents indicated for and under investigation for R/R MM
  • Select optimal therapies for patients with heavily pretreated R/R MM based on individual patient and disease characteristics
  • Manage toxicities with newer agents and combination regimens in patients with heavily pretreated R/R MM
  • Identify patients with R/R MM who would be eligible for enrollment in late-phase clinical trials

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.